Minerva Neurosciences Inc Cash Flow Conversion Efficiency
Minerva Neurosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Minerva Neurosciences Inc (NERV) has a cash flow conversion efficiency ratio of 21.365x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.43 Billion) by net assets ($-254.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Minerva Neurosciences Inc (2012–2025)
Cash flow conversion efficiency of Minerva Neurosciences Inc from 2012 to 2025. This chart illustrates how Minerva Neurosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Minerva Neurosciences Inc for real-time trading data and today's change.
Minerva Neurosciences Inc Cash Flow Conversion Ratio Explained
Minerva Neurosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Minerva Neurosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Minerva Neurosciences Inc ranked by their cash flow conversion efficiency. Also see NERV market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Besiktas Futbol Yatirimlari Sanayi ve Ticaret AS
IS:BJKAS
|
0.286x |
|
MTM Critical Metals Ltd
AU:MTM
|
-0.097x |
|
Apyx Medical Inc
NASDAQ:APYX
|
-0.315x |
|
Sam Young Chem
KO:003720
|
0.149x |
|
Humanica Public Company Limited
BK:HUMAN
|
0.044x |
|
San Lien Technology
TWO:5493
|
0.050x |
|
Orthocell Ltd
AU:OCC
|
-0.211x |
|
Noroo Paint
KO:090350
|
0.064x |
Annual Cash Flow Conversion Efficiency for Minerva Neurosciences Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Minerva Neurosciences Inc from 2012 to 2025. Review NERV free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-140.75 Million | $-13.51 Billion | 95.994x | +12515.38% |
| 2024-12-31 | $-25.69 Million | $-19.55 Million | 0.761x | +46.46% |
| 2023-12-31 | $-28.46 Million | $-14.78 Million | 0.520x | -57.79% |
| 2022-12-31 | $-20.02 Million | $-24.65 Million | 1.231x | +139.90% |
| 2021-12-31 | $7.98 Million | $-24.60 Million | -3.085x | -380.29% |
| 2020-12-31 | $52.66 Million | $-33.82 Million | -0.642x | +58.92% |
| 2019-12-31 | $27.78 Million | $-43.43 Million | -1.563x | -236.48% |
| 2018-12-31 | $90.26 Million | $-41.94 Million | -0.465x | -2077.04% |
| 2017-12-31 | $131.60 Million | $3.09 Million | 0.024x | +109.70% |
| 2016-12-31 | $105.98 Million | $-25.69 Million | -0.242x | +44.75% |
| 2015-12-31 | $55.32 Million | $-24.27 Million | -0.439x | +37.17% |
| 2014-12-31 | $51.50 Million | $-35.96 Million | -0.698x | -552.28% |
| 2013-12-31 | $20.18 Million | $-2.16 Million | -0.107x | +99.78% |
| 2012-12-31 | $19.02K | $-908.54K | -47.770x | -- |
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in… Read more